Lisata Therapeutics (NASDAQ:LSTA) Rating Lowered to “Hold” at Zacks Research

Lisata Therapeutics (NASDAQ:LSTA) was downgraded by research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Monday,Zacks.com reports.

Several other research firms have also issued reports on LSTA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Lisata Therapeutics in a research note on Thursday, August 21st. Finally, Brookline Capital Management lifted their price target on Lisata Therapeutics from $20.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, July 15th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $23.50.

Lisata Therapeutics Stock Performance

LSTA opened at $2.10 on Monday. Lisata Therapeutics has a 52-week low of $1.87 and a 52-week high of $4.20. The firm has a market capitalization of $18.39 million, a PE ratio of -0.94 and a beta of 1.01. The business’s 50-day simple moving average is $2.40 and its 200 day simple moving average is $2.50.

Lisata Therapeutics (NASDAQ:LSTA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.05. On average, research analysts forecast that Lisata Therapeutics will post -2.66 earnings per share for the current year.

Institutional Trading of Lisata Therapeutics

A hedge fund recently bought a new stake in Lisata Therapeutics stock. Cerity Partners LLC purchased a new stake in Lisata Therapeutics, Inc. (NASDAQ:LSTA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 12,183 shares of the company’s stock, valued at approximately $32,000. Cerity Partners LLC owned 0.14% of Lisata Therapeutics at the end of the most recent reporting period. Institutional investors and hedge funds own 8.94% of the company’s stock.

About Lisata Therapeutics

Lisata Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease.